Product IntroductionBioactivity英文名:
RKS-262描述: RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several non-small cell lung cancer cell lines and few cell lines from other tissues were relatively resistant (GI(50) > 1 µM) to RKS262 treatment.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
关键字:
KP 1678 |
KP-1678 |
KP1678 |
KAI 1678 |
KAI1678 |
RKS 262 |
RKS262 |
RKS-262